1. 1. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology, 22(8): 1736-47. [DOI:10.1093/annonc/mdr304]

2. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast, 24(Suppl 2), S26-S35. [DOI:10.1016/j.breast.2015.07.008]

3. Huang L, Snyder AR, Morgan WF (2003) Radiation-induced genomic instability and its implications for radiation carcinogenesis. Oncogene, 22(37): 5848-54. doi: 10.1038/sj.onc.1206697. PMID: 12947391. [DOI:10.1038/sj.onc.1206697]

4. Mozdarani H (2016) Breast cancer and paradigm of genomic instability. Arch Breast Cancer, 3 (4): 102-105.

5. Scott D (1999) Increased chromosomal radiosensitivity in breast cancer patients: a comparison of two assays. Int J Radiati Biol, 75(1): 1-10. [DOI:10.1080/095530099140744]

6. Shahidi M, Mozdarani H, Bryant PE (2007) Radiation sensitivity of leukocytes from healthy individuals and breast cancer patients as measured by the alkaline and neutral comet assay. Cancer Letters, 257: 263-273. [DOI:10.1016/j.canlet.2007.08.002]

7. El-Nachef L, Al-Choboq J, Restier-Verlet J, Granzotto A, Berthel E, Sonzogni L, et al. (2021) Human Radiosensitivity and Radiosusceptibility: What Are the Differences? Int J Mol Sci, 22(13): 7158. [DOI:10.3390/ijms22137158]

8. Mozdarani H, Salimi M, Bakhtari N (2017) Inherent radiosensitivity and its impact on breast cancer chemo-radiotherapy. Int J Radiat Res, 15(4): 325-41.

9. Sies H and Jones DP (2022) Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol, 23(6): 363-381. [DOI:10.1038/s41580-021-00455-6]

10. Salimi M and Mozdarani H (2015) Different aspects of cytochalasin B Blocked micronucleus cytome (CBMN cyt) assay as a comprehensive measurement tool for radiobiological studies, biological dosimetry and genome instability. Int J Radiat Res, 13(2): 101-126.

11. Fenech M (2020) Cytokinesis-Block Micronucleus Cytome Assay Evolution into a More Comprehensive Method to Measure Chromosomal Instability. Genes, 11(10): 1203. [DOI:10.3390/genes11101203]

12. Montoro A, Obrador E, Mistry D, Forte GI, Bravatà V, Minafra L, et al. (2023) Radioprotectors, Radiomitigators, and Radiosensitizers. in Radiobiology textbook; Sarah Baatout (ed.); pp: 571-628, Springer. [DOI:10.1007/978-3-031-18810-7_11]

13. Najafi M, Shirazi A, Motevaseli E, Rezaeyan A, Salajegheh A, Rezapoor S (2017) Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology, 25(4): 403-13. [DOI:10.1007/s10787-017-0332-5]

14. Farhood B, Goradel N, Mortezaee K, Khanlarkhani N, Salehi E, Nashtaei M, et al. (2019) Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clinical and Translational Oncology, 21(3): 268-79. [DOI:10.1007/s12094-018-1934-0]

15. Mediavilla MD, Sanchez-Barcelo EJ, Tan DX, Manchester L, Reiter RJ (2010) Basic mechanisms involved in the anti-cancer effects of melatonin. Curr Med Chem, 17(36): 4462-4481. [DOI:10.2174/092986710794183015]

16. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, Yang SF, et al. (2017) Melatonin, a full-service anti-cancer agent: inhibition of initiation, progression and metastasis. Int J Mol Sci, 18(4): 843. [DOI:10.3390/ijms18040843]

17. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzalez C, Reiter RJ (2012) Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs, 21(6): 819-831. [DOI:10.1517/13543784.2012.681045]

18. Galano A, Tan DX, Reiter RJ (2011) Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res, 51(1): 1-16. [DOI:10.1111/j.1600-079X.2011.00916.x]

19. Rodriguez C, Mayo JC, Sainz RM, Antolín I, Herrera F, Martín V, et al. (2004) Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res, 36(1): 1-9. [DOI:10.1046/j.1600-079X.2003.00092.x]

20. Huang CC, Lai CJ, Tsai MH, Wu YC, Chen KT, Jou MJ, et al. (2015) Effects of melatonin on the nitric oxide system and protein nitration in the hypobaric hypoxic rat hippocampus. BMC Neurosci, 16: 61. [DOI:10.1186/s12868-015-0199-6]

21. Johnke RM, Sattler JA, Allison RR (2014) Radioprotective agents for radiation therapy: future trends. Future Oncol, 10(15):2345 -2357. [DOI:10.2217/fon.14.175]

22. Skourtis G, Krontira A, Ntaoula S, Ferlemi AV, Zeliou K, Georgakopoulos C, et al. (2020) Protective antioxidant effects of saffron extract on retinas of streptozotocin-induced diabetic rats. Romanian Journal of Ophthalmology, 64(4): 394. [DOI:10.22336/rjo.2020.61]

23. Premkumar K, Thirunavukkarasu C, Abraham SK, Santhiya ST, Ramesh A (2006) Protective effect of saffron (Crocus sativus L.) aqueous extract against genetic damage induced by anti-tumor agents in mice. Hum Exp Toxicol, 25(2):79-84. [DOI:10.1191/0960327106ht589oa]

24. Farahmand SK, Samini F, Samini M, Samarghandian S (2013) Safranal ameliorates antioxidant enzymes and suppresses lipid peroxidation and nitric oxide formation in aged male rat liver. Biogerontology, 14: 63-71. [DOI:10.1007/s10522-012-9409-0]

25. Samarghandian S, Afshari JT, Davoodi S (2011) Suppression of pulmonary tumor promotion and induction of apoptosis by Crocus sativus L. extraction. Appl Biochem Biotechnol, 164: 238-247. [DOI:10.1007/s12010-010-9130-x]

26. Samarghandian S and Borji A (2014) Anticarcinogenic effect of saffron (Crocus sativus L.) and its ingredients. Pharmacogn Res, 6: 99-107. [DOI:10.4103/0974-8490.128963]

27. Fenech M (2010) The lymphocyte cytokinesis-block micronucleus cytome assay and its application in radiation biodosimetry. Health Physics, 98(2): 234-43. [DOI:10.1097/HP.0b013e3181b85044]

28. Hadizadeh F, Mohajeri S, Seifi M (2010) Extraction and purification of crocin from saffron stigmas employing a simple and efficient crystallization method. Pak J Biol Sci, 13(14): 691-8. [DOI:10.3923/pjbs.2010.691.698]

29. Escala CRA, Muñoz GM, Hernández AO, de Salas MS, Muñoz MAG, Ampuero JC, et al. (2020) Identifying the best Ki67 cut-off for determining luminal breast cancer subtypes using immunohistochemical analysis and PAM50 genomic classification. Open Archive ESMO Annals of Oncology, 31 (Supplement 4): S327 [DOI:10.1016/j.annonc.2020.08.337]

30. Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, et al. (2014) Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information. Clinical Medicine Insights: Oncology, 8: S18006. [DOI:10.4137/CMO.S18006]

31. Fenech M (2020) Cytokinesis-Block micronucleus cytome assay evolution into a more comprehensive method to measure chromosomal instability. Genes, 11(10): 1203. [DOI:10.3390/genes11101203]

32. Mozdarani H, Ziaee Mashhadi A, Alimohammadi (2011) G2 chromosomal radiosensitivity and background frequency of sister chromatid exchanges of peripheral blood lymphocytes of breast cancer patients. Int J Radiat Res, 9 (3): 167-174.

33. Mozdarani H, Mansouri Z, Haeri SA (2005) Cytogenetic radiosensitivity of g0-lymphocytes of breast and esophageal cancer patients as determined by micronucleus assay. J Radiat Res, 46(1): 111-6. [DOI:10.1269/jrr.46.111]

34. Colleu-Durel S, Guitton N, Nourgalieva K, Legue F, Leveque J, Danic B, et al. (2004) Alkaline single-cell gel electrophoresis (comet assay): a simple technique to show genomic instability in sporadic breast cancer. Eur J Can, 40(3): 445-51. [DOI:10.1016/j.ejca.2003.09.033]

35. Parshad R, Price F, Bohr V, Cowans K, Zujewski J, Sanford K (1996) Deficient DNA repair capacity, a predisposing factor in breast cancer. Br J Can, 74(1):1-5. [DOI:10.1038/bjc.1996.307]

36. Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM, Baade PD (2012) The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol, 36(3): 237-48. [DOI:10.1016/j.canep.2012.02.007]

37. Smart V, Curwen G, Whitehouse C, Edwards A, Tawn E (2003) Chromosomal radiosensitivity: a study of the chromosomal G2 assay in human blood lymphocytes indicating significant inter-individual variability. Mut Res/Fund Mol Mech Mutagen, 528(1-2): 105-10. [DOI:10.1016/S0027-5107(03)00076-9]

38. Baeyens A, Thierens H, Claes K, Poppe B, Messiaen L, De Ridder L, et al. (2002) Chromosomal radiosensitivity in breast cancer patients with a known or putative genetic predisposition. Br J cancer, 87(12): 1379-85. [DOI:10.1038/sj.bjc.6600628]

39. Vral A, Thierens H, Baeyens A, De Ridder L (2002) The micronucleus and G2-phase assays for human blood lymphocytes as biomarkers of individual sensitivity to ionizing radiation: limitations imposed by intraindividual variability. Radiat Res, 157(4): 472-7. [DOI:10.1667/0033-7587(2002)157[0472:TMAGPA]2.0.CO;2]

40. Poggioli T, Sterpone S, Palma S, Cozzi R, Testa A (2010) G0 and G2 chromosomal assays in the evaluation of radiosensitivity in a cohort of Italian breast cancer patients. J Radiat Res, 51(5): 615-9. [DOI:10.1269/jrr.10052]

41. Smith TA, Kirkpatrick DR, Smith S, Smith TK, Pearson T, Kailasam A, et al. (2017) Radioprotective agents to prevent cellular damage due to ionizing radiation. J Translat Med, 15(1): 1-18. [DOI:10.1186/s12967-017-1338-x]

42. Mohan G, TP AH, Jijo A, KM SD, Narayanasamy A, Vellingiri B (2019) Recent advances in radiotherapy and its associated side effects in cancer-a review. The Journal of Basic and Applied Zoology, 80(1): 1-10. [DOI:10.1186/s41936-019-0083-5]

43. Hosseinzadeh H, Younesi HM (2002) Antinociceptive and anti-inflammatory effects of Crocus sativus L. stigma and petal extracts in mice. BMC Pharmacol, 2: 7. [DOI:10.1186/1471-2210-2-7]

44. Premkumar K, Thirunavukkarasu C, Abraham S, Santhiya S, Ramesh A (2006) Protective effect of saffron (Crocus sativus L.) aqueous extract against genetic damage induced by anti-tumor agents in mice. Human Exp Toxicol, 25(2): 79-84. [DOI:10.1191/0960327106ht589oa]

45. Mozdarani H, Pakniyat F, Mozdarani S, Nosrati H (2021) Effects of saffron extract on the frequency of radiation induced chromosomal aberration in G2-lymphocytes of normal individuals and breast cancer patients. Int J Radiat Res, 19(3): 711-17. [DOI:10.52547/ijrr.19.3.711]

46. Samei E, Mozdarani H, Samiei F, Javadi G (2020) Radiosensitizing effects of melatonin on radiation induced chromosomal aberration in G2-lymphocytes of breast cancer patients. Int J Radiat Res,18(4): 657-62. [DOI:10.52547/ijrr.18.4.657]

47. Reiter RJ, Tan DX, Galano A (2014) Melatonin reduces lipid peroxidation and membrane viscosity. Front Physiol, 5: 377 [DOI:10.3389/fphys.2014.00377]

48. Yuan L, Collins AR, Dai J, Dubocovich ML, Hill SM (2002) MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol, 192(1-2): 147-156. [DOI:10.1016/S0303-7207(02)00029-1]

49. Shirazi A, Haddadi G, Minaee B, Sepehrizadeh Z, Mahdavi S, Jaberi E, et al. (2010) Evaluation of melatonin for modulation of apoptosis-related genes in irradiated cervical spinal cord. Int J Low Radiat, 7(6): 436-45. [DOI:10.1504/IJLR.2010.037665]